Article
Oncology
Manon Queudeville, Anthony S. Stein, Franco Locatelli, Martin Ebinger, Rupert Handgretinger, Nicola Goekbuget, Lia Gore, Yi Zeng, Priya Gokani, Gerhard Zugmaier, Hagop M. Kantarjian
Summary: The study found that a lower baseline bone marrow blast percentage (bBMB%) is associated with better treatment outcomes in patients with B-cell acute lymphoblastic leukemia (B-ALL) receiving blinatumomab. This suggests that bBMB% <50% is associated with improved efficacy following blinatumomab treatment for B-ALL.
Article
Hematology
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O'Dwyer, Houston Holmes, Martha L. Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda
Summary: The ZUMA-3 study evaluated the efficacy and safety of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. The treatment showed a high response rate and tolerable safety profile, with revised adverse event management strategies helping to optimize the risk-benefit ratio.
Article
Oncology
Katarzyna Pawinska-Wasikowska, Aleksandra Wieczorek, Walentyna Balwierz, Karolina Bukowska-Strakova, Marta Surman, Szymon Skoczen
Summary: This study retrospectively assessed the efficacy and toxicity of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The results showed that blinatumomab is not only a feasible therapeutic option, but also an effective treatment with acceptable toxicity profile in pretreated children with relapsed/refractory BCP-ALL, paving the way for hematopoietic stem cell transplantation (HSCT).
Article
Medicine, General & Internal
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Chaoling Feng, Jinghui Dong, Tong Shen, Francesca Milletti, John M. Rossi, Remus Vezan, Behzad Kharabi Masouleh, Roch Houot
Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.
Article
Oncology
Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier, Anthony S. Stein, Herve Dombret, Yuqi Chen, Josep-Maria Ribera, Ralf C. Bargou, Heinz-August Horst, Hagop M. Kantarjian
Summary: This study analyzed long-term follow-up data from two clinical trials involving blinatumomab, finding that one-third of patients with relapsed and/or refractory B-cell precursor acute lymphoblastic leukemia achieving a deep response with blinatumomab lived for 3 years or longer. These results suggest that long-term survival is possible after treatment with blinatumomab, with some patients even undergoing stem cell transplantation showing improved survival outcomes.
Article
Oncology
Hagop M. Kantarjian, Gerhard Zugmaier, Monika Brueggemann, Brent L. Wood, Heinz A. Horst, Yi Zeng, Giovanni Martinelli
Summary: The study compared the effects of blinatumomab treatment with chemotherapy on bone marrow function in ALL patients, showing that blinatumomab treatment led to temporary myelosuppression with greater survival benefits compared to chemotherapy.
Article
Oncology
Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani
Summary: Inotuzumab ozogamicin demonstrated superior response rates, minimal/measurable residual disease negativity, longer duration of remission, and better overall survival compared to standard of care in patients with CD22 positivity >= 90%. Patients with CD22 positivity <90% showed higher response rates with inotuzumab ozogamicin therapy, but similar duration of remission and overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Valeria Ceolin, Erica Brivio, Harm van Tinteren, Susan R. Rheingold, Allison Leahy, Britta Vormoor, Maureen M. O'Brien, Jeremy D. Rubinstein, Krzysztof Kalwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, Monica Lopez-Duarte, Bianca F. Goemans, Franco Locatelli, Peter Hoogerbrugge, Friso G. Calkoen, Christian Michel Zwaan
Summary: A retrospective analysis of 39 children and young adults who received inotuzumab ozogamicin (InO) before and/or after CAR T-cell therapy showed that the efficacy and survival rates of patients treated with InO prior to or after CAR T-cell therapy were similar to those without prior InO treatment.
Article
Oncology
Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver Ottmann, Nicola Goekbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine A. Tuglus, Joan D. Morris, Anthony Stein
Summary: The study evaluated the long-term durability of Blinatumomab in adults with relapsed/refractory Ph+ B-cell precursor acute lymphoblastic leukemia, showing that 35.6% of patients achieved complete remission within the first two treatment cycles. The median overall survival was 9.0 months, with a longer duration seen in patients who achieved complete remission.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Talha Badar, Aniko Szabo, Shira Dinner, Michaela Liedtke, Madelyn Burkart, Rory M. Shallis, Ilana R. Yurkiewicz, Eric Kuo, Muhammad Ali Khan, Suresh Balasubramanian, Jay Yang, Mehrdad Hefazi, Nikolai Podoltsev, Anand Patel, Emily Curran, Amy Wang, Shukaib Arslan, Ibrahim Aldoss, Caitlin Siebenaller, Ryan J. Mattison, Mark R. Litzow, Martha Wadleigh, Anjali S. Advani, Ehab Atallah
Summary: A study comparing the efficacy of blinatumomab and InO as first or second NA therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia found that the two agents may have comparable efficacy in this setting.
Article
Hematology
Erica Brivio, Franco Locatelli, Marta Lopez-Yurda, Andrea Malone, Cristina Diaz-de-Heredia, Bella Bielorai, Claudia Rossig, Vincent H. J. van der Velden, Anneke C. J. Ammerlaan, Adriana Thano, Inge M. van der Sluis, Monique L. den Boer, Ying Chen, Barbara Sleight, Benoit Brethon, Karsten Nysom, Lucie Sramkova, Ingrid Ora, Luciana Vinti, Christiane Chen-Santel, Christian Michel Zwaan
Summary: This phase 1 study investigated the efficacy and safety of inotuzumab ozogamicin in pediatric patients with acute lymphoblastic leukemia, establishing the recommended phase 2 dose as 1.8 mg/m(2). The treatment showed promising efficacy and good tolerability, with potential clinical implications.
Article
Oncology
Nicola Stefano Fracchiolla, Mariarita Sciume, Cristina Papayannidis, Antonella Vitale, Sabina Chiaretti, Mario Annunziata, Fabio Giglio, Prassede Salutari, Fabio Forghieri, Davide Lazzarotto, Monia Lunghi, Annalisa Imovilli, Barbara Scappini, Massimiliano Bonifacio, Michelina Dargenio, Carmela Gurrieri, Elisabetta Todisco, Marzia Defina, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Cerrano, Lidia Santoro, Elena Tagliaferri, Enrico Barozzi, Pasquale De Roberto, Marta Canzi, Elisa Buzzatti, Chiara Sartor, Francesco Passamonti, Robin Foa, Antonio Curti, Thomas Wirth
Summary: This retrospective study evaluated the efficacy and safety of blinatumomab and inotuzumab ozogamicin in the treatment of relapsed B-lymphoblastic leukemia. The study demonstrated the feasibility and effectiveness of sequential immunotherapy using these two drugs in terms of minimal residual disease, overall survival, and disease-free survival.
Article
Oncology
Ekaterina Mikhailova, Olga Illarionova, Alexander Komkov, Elena Zerkalenkova, Ilgar Mamedov, Larisa Shelikhova, Yulia Olshanskaya, Natalia Miakova, Galina Novichkova, Alexander Karachunskiy, Michael Maschan, Alexander Popov
Summary: This study aimed to develop an antibody panel and data analysis algorithm for reliable minimal residual disease (MRD) detection in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients treated with CD19-directed therapy. The approach was adapted for possible CD19 loss and showed high qualitative concordance rates when compared to molecular techniques.
Review
Pharmacology & Pharmacy
Bin Chen, Zhuan Zou, Qian Zhang, Kexing Chen, Xiaoyan Zhang, Dongqiong Xiao, Xihong Li
Summary: This meta-analysis confirms the efficacy and safety of blinatumomab in pediatric patients with relapsed/refractory B-ALL. The results show that blinatumomab has positive outcomes in terms of CR, OS, EFS, MRD response, and allo-HSCT in single-arm studies, with limited adverse effects. In comparison to chemotherapy, blinatumomab demonstrates superior OS and EFS rates in randomized controlled trials. Overall, blinatumomab shows promising therapeutic efficacy and safety in children with R/R B-ALL.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Hematology
Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulalia Genesca, Pere Barba, Jordi Ribera, Irene Garcia-Cadenas, Maria Jose Moreno, Daniel Martinez-Carballeira, Anna Torrent, Pilar Martinez-Sanchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, Maria Teresa Artola, Marta Cervera, Jose Gonzalez-Campos, Carlos Rodriguez, Arancha Bermudez, Andres Novo, Beatriz Soria, Rosa Coll, Maria-Luz Amigo, Aurelio Lopez-Martinez, Rosa Fernandez-Martin, Josefina Serrano, Santiago Mercadal, Antonia Cladera, Alberto Gimenez-Conca, Maria-Jesus Penarrubia, Eugenia Abella, Ferran Vall-llovera, Jesus-Maria Hernandez-Rivas, Antoni Garcia-Guinon, Juan-Miguel Bergua, Beatriz de Rueda, Maria-Jose Sanchez-Sanchez, Alfons Serrano, Maria Calbacho, Natalia Alonso, Jose-Angel Mendez-Sanchez, Raimundo Garcia-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao
Summary: The study evaluated the outcomes of high-risk Ph- adult ALL patients treated with chemotherapy or allo-HSCT, finding that avoiding allo-HSCT for patients with adequate MRD response does not affect outcomes.
Article
Orthopedics
Marta del Rio-Arteaga, Jesus Payo-Ollero, Mercedes Vallejo, David Serrano-Toledano, Boris Garcia-Benitez, Juan Ribera
Summary: Short stem implants showed promising medium-term results for young patients, with significant improvements in clinical, functional, and quality-of-life outcomes. Radiological analysis revealed no radiolucencies or stress shielding, indicating the potential success of using short stems for total hip replacement in this patient group.
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
(2022)
Article
Cell Biology
Maria Joao Baptista, Gustavo Tapia, Ana-Maria Munoz-Marmol, Josep Muncunill, Olga Garcia, Silvia Montoto, John G. Gribben, Maria Calaminici, Antonio Martinez, Luis Veloza, Alejandra Martinez-Trillos, Teresa Aldamiz, Javier Menarguez, Maria-Jose Terol, Antonio Ferrandez, Miguel Alcoceba, Javier Briones, Eva Gonzalez-Barca, Fina Climent, Ana Muntanola, Jose-Maria Moraleda, Mariano Provencio, Pau Abrisqueta, Eugenia Abella, Lluis Colomo, Carlos Garcia-Ballesteros, Montserrat Garcia-Caro, Juan-Manuel Sancho, Josep-Maria Ribera, Jose-Luis Mate, Jose-Tomas Navarro
Summary: This study characterized HIV-associated aggressive B-cell non-Hodgkin lymphoma (B-NHL) using immunohistochemistry and genetic analysis, and found that the phenotypic and genotypic features of HIV-associated aggressive B-NHL are similar to those of the general population. However, the frequency of BCL2 rearrangement is low in DLBCL, and the coexpression of MYC and BCL2 in DLBCL and the expression of MUM-1 in BL are associated with a worse prognosis.
Review
Oncology
Josep-Maria Ribera, Sabina Chiaretti
Summary: The use of tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia has made significant progress. Modern management strategies include early use of third-generation inhibitors, combination with immunotherapy, optimized maintenance therapy, and targeted therapies for patients with molecular or hematological relapse. Improvements in the assessment of measurable residual disease and the detection of mutations in the ABL1 domain contribute to better treatment selection.
Article
Public, Environmental & Occupational Health
Alexandra Fehr, Claudia Nieto-Sanchez, Joan Muela, Ebrima Manneh, Dullo Baldeh, Omar Ceesay, Umberto D'Alessandro, Edgard Dabira, Patricia Kingori, Koen Peeters Grietens, Azucena Bardaji, Joske Bunders-Aelen, Teun Zuiderent-Jerak
Summary: This study aims to expand the understanding of fieldworkers, emphasizing the importance of their roles and interactions within the trial community. The research found that fieldworkers engage in "reciprocity work" through their regular tasks and interactions, which impacts the trial and individuals' autonomy in decision-making. Understanding the role of fieldworkers and their reciprocity work is crucial for comprehending research ethics in global health research.
GLOBAL PUBLIC HEALTH
(2022)
Article
Hematology
Ana C. Oliveira, Josep Maria Roncero, Christelle Ferra, Janilson Do Nascimento, Marta Rodriguez-Luaces, Maite Encuentra, Eva Domingo-Domenech, Patricia Lopez, David Gallardo, Josep Maria Ribera, Josep Sarra, Anna Sureda, Eva Gonzalez-Barca
Summary: FCR is an effective front-line treatment for CLL, with a high overall response rate and complete response rate. However, a significant proportion of patients may require subsequent therapies. BTKi therapy shows better outcomes in terms of third-treatment free survival compared to chemotherapy +/- antiCD20 strategies.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foa, Alessandro Rambaldi
Summary: This retrospective study included adult patients with B-cell ALL who were treated with blinatumomab for MRD+ or R/R B-cell ALL. The results showed significant treatment responses and survival benefits in both groups of patients.
BLOOD CANCER JOURNAL
(2023)
Letter
Hematology
Pere Barba, Mireia Morgades, Pau Montesinos, Jose Gonzalez-Campos, Anna Torrent, Cristina Gil, Teresa Bernal, Mar Tormo, Santiago Mercadal, Sandra Novoa, Irene Garcia-Cadenas, M. Paz Queipo de Llano, Marta Cervera, Rosa Coll, Arancha Bermudez, M. Luz Amigo, Silvia Monsalvo, Jordi Esteve, Raimundo Garcia-Boyero, Andres Novo, Jesus Maria Hernandez Rivas, Antonia Cladera, Pilar Martinez-Sanchez, Josefina Serrano, Maria Teresa Artola, Beatriz Soria, Eugenia Abella, Ferran Vall-Llovera, Juan Bergua, Pilar Herrera, Daniel Barrios, Josep Maria Ribera
Article
Medicine, Research & Experimental
Josep-Maria Ribera, Thibaud Prawitz, Andreas Freitag, Anuj Sharma, Balazs Dobi, Federica Rizzo, Lorenzo Sabatelli, Petros Patos
Summary: The efficacy of ponatinib-based treatments compared to imatinib-based treatments in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) was evaluated. The results showed that ponatinib-based treatments had better outcomes in terms of overall survival and complete molecular response compared to imatinib-based treatments.
ADVANCES IN THERAPY
(2023)
Editorial Material
Hematology
Josep-Maria Ribera
Summary: In this study, the prognostic significance of central nervous system (CNS) leukemic involvement in children and young adults diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) was assessed. Patients with CNS-1 or CNS-2 status at diagnosis had similar event-free survival (EFS) and overall survival (OS), which were significantly better than those of patients with CNS-3 status.
Editorial Material
Hematology
Josep-Maria Ribera
Summary: In this study published in Blood, Maese et al. demonstrated that IM JZP458 at a dose of 25/25/50 mg/m(2) administered thrice weekly can serve as a reliable and safe alternative for patients who are hypersensitive to E. coli-derived asparaginases.
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Review
Medicine, General & Internal
Marta Canelo-Vilaseca, Gustavo Tapia, Elisa Orna, Marc Sorigue, Isabel Granada, Azahara Palomar-Munoz, Ana Castillo, Javier Grau, Alba Mesa, Josep-Maria Ribera, Juan-Manuel Sancho, Jose-Tomas Navarro
Summary: Key Clinical Message: HHV8- and EBV-negative primary effusion lymphoma is an extremely rare neoplasm involving body cavities without detectable tumor mass. It usually presents in elderly patients without known immunodeficiency. Compared to primary effusion lymphoma, it has a better prognosis.
CLINICAL CASE REPORTS
(2023)
Meeting Abstract
Hematology
Cristina de-la-Fuente, Ines Hernandez-Rodriguez, Mireia Morgades, Cristian Morales-Indiano, Josep-Maria Ribera, Alba Leis-Sestayo, Alicia Martinez-Iribarren, Jose-Tomas Navarro
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
P. Paredes Barranco, A. Fritsch Medina, N. Agusti, B. Diaz-Feijoo, F. Campos, J. Cases, J. Ribera, I. Romero, A. Glickman, A. Torne, N. Sanchez-Izquierdo, M. Santos Virosta, S. Vidal-Sicart
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Hematology
Martin Dreyling, Marc Andre, Nicola Gokbuget, Herve Tilly, Mats Jerkeman, John Gribben, Andres Ferreri, Pierre Morel, Stephan Stilgenbauer, Christopher Fox, Jose Maria Ribera, Sonja Zweegman, Igor Aurer, Csaba Bodor, Birgit Burkhardt, Christian Buske, Maria Dollores Caballero, Elias Campo, Bjoern Chapuy, Andrew Davies, Laurence de Leval, Jeanette Doorduijn, Massimo Federico, Philippe Gaulard, Francesca Gay, Paolo Ghia, Kirsten Gronbaek, Hartmut Goldschmidt, Marie-Jose Kersten, Barbara Kiesewetter, Judith Landman-Parker, Steven Le Gouill, Georg Lenz, Sirpa Leppa, Armando Lopez-Guillermo, Elizabeth Macintyre, Maria Victoria Mateos Mantega, Philippe Moreau, Carol Moreno, Bertrand Nadel, Jessica Okosun, Roger Owen, Sarka Pospisilova, Christiane Pott, Tadeusz Robak, Michelle Spina, Kostas Stamatopoulos, Jan Stary, Karin Tarte, Allessandra Tedeschi, Catherine Thieblemont, Ralf Ulrich Trappe, Lorenz H. Trumper, Gilles Salles
